Arginine vasopressin in septic shock

supplement or substitute for norepinephrine?

Sebastian Rehberg, Perenlei Enkhbaatar, Daniel L. Traber

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the current issue of Critical Care, Simon and coworkers investigated the effects of first-line arginine vasopressin (AVP) on organ function and systemic metabolism compared with norepinephrine in a pig model of fecal peritonitis. AVP was titrated according to the mean arterial pressure suggesting a vasopressor rather than a hormone replacement therapy. The study provides some evidence for the safety of this therapeutic approach. It needs to be determined whether AVP is most beneficial as a constant low-dose infusion to supplement norepinephrine or in higher doses than currently recommended to substitute norepinephrine. In addition, future studies are warranted to evaluate whether a first-line therapy of AVP is superior to a last-resort administration.

Original languageEnglish (US)
Pages (from-to)178
Number of pages1
JournalCritical care (London, England)
Volume13
Issue number4
StatePublished - 2009

Fingerprint

Arginine Vasopressin
Septic Shock
Norepinephrine
Hormone Replacement Therapy
Critical Care
Peritonitis
Arterial Pressure
Swine
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Arginine vasopressin in septic shock : supplement or substitute for norepinephrine? / Rehberg, Sebastian; Enkhbaatar, Perenlei; Traber, Daniel L.

In: Critical care (London, England), Vol. 13, No. 4, 2009, p. 178.

Research output: Contribution to journalArticle

@article{50c1d650d96748d8b2410a6d9956741a,
title = "Arginine vasopressin in septic shock: supplement or substitute for norepinephrine?",
abstract = "In the current issue of Critical Care, Simon and coworkers investigated the effects of first-line arginine vasopressin (AVP) on organ function and systemic metabolism compared with norepinephrine in a pig model of fecal peritonitis. AVP was titrated according to the mean arterial pressure suggesting a vasopressor rather than a hormone replacement therapy. The study provides some evidence for the safety of this therapeutic approach. It needs to be determined whether AVP is most beneficial as a constant low-dose infusion to supplement norepinephrine or in higher doses than currently recommended to substitute norepinephrine. In addition, future studies are warranted to evaluate whether a first-line therapy of AVP is superior to a last-resort administration.",
author = "Sebastian Rehberg and Perenlei Enkhbaatar and Traber, {Daniel L.}",
year = "2009",
language = "English (US)",
volume = "13",
pages = "178",
journal = "Critical Care",
issn = "1364-8535",
publisher = "BioMed Central Ltd.",
number = "4",

}

TY - JOUR

T1 - Arginine vasopressin in septic shock

T2 - supplement or substitute for norepinephrine?

AU - Rehberg, Sebastian

AU - Enkhbaatar, Perenlei

AU - Traber, Daniel L.

PY - 2009

Y1 - 2009

N2 - In the current issue of Critical Care, Simon and coworkers investigated the effects of first-line arginine vasopressin (AVP) on organ function and systemic metabolism compared with norepinephrine in a pig model of fecal peritonitis. AVP was titrated according to the mean arterial pressure suggesting a vasopressor rather than a hormone replacement therapy. The study provides some evidence for the safety of this therapeutic approach. It needs to be determined whether AVP is most beneficial as a constant low-dose infusion to supplement norepinephrine or in higher doses than currently recommended to substitute norepinephrine. In addition, future studies are warranted to evaluate whether a first-line therapy of AVP is superior to a last-resort administration.

AB - In the current issue of Critical Care, Simon and coworkers investigated the effects of first-line arginine vasopressin (AVP) on organ function and systemic metabolism compared with norepinephrine in a pig model of fecal peritonitis. AVP was titrated according to the mean arterial pressure suggesting a vasopressor rather than a hormone replacement therapy. The study provides some evidence for the safety of this therapeutic approach. It needs to be determined whether AVP is most beneficial as a constant low-dose infusion to supplement norepinephrine or in higher doses than currently recommended to substitute norepinephrine. In addition, future studies are warranted to evaluate whether a first-line therapy of AVP is superior to a last-resort administration.

UR - http://www.scopus.com/inward/record.url?scp=75549090750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75549090750&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 178

JO - Critical Care

JF - Critical Care

SN - 1364-8535

IS - 4

ER -